Roivant Sciences Ltd.
Roivant Sciences Ltd. is a healthcare company focused on developing and commercializing medicines, with a single executive branch holding by Howard Lutnick valued between $1M-$5M and one congressional trader executing 8 transactions in 2025.
BusinessWhat ROIV does
Roivant Sciences Ltd. operates as a healthcare company that identifies, develops, and commercializes innovative medicines across various therapeutic areas. Its business model involves creating subsidiary companies (Vants) to advance drug candidates, leveraging partnerships and strategic investments. Revenue is generated through drug development collaborations, licensing agreements, and potential future product sales.
12 months past · 3 months futureROIV activity timeline
Executive Branch ConflictsROIV held by Trump-administration officials
Lifetime Government AwardsROIV federal contracts
ROIV doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding ROIV
Politicians Trading ROIVMembers of Congress with recent ROIV positions
Congressional TradesWho in Congress is trading ROIV
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting ROIVLive legislation impacting this stock
Political ProfileWhere ROIV sits in Washington
[object Object]
STRUCTURAL: No lobbying spend (get_political_influence.lobbying.total_income: 0), no donations, no federal contracts (get_government_precedent.federal_contracts_summary: null). EVIDENTIARY: Single executive branch holding by Howard Lutnick valued $1M-$5M (get_executive_branch_exposure.by_ticker[0].holdings[0].value_bucket), one congressional trader (M001136) with 8 mixed transactions in 2025. Net: Limited direct political engagement but some high-level exposure.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
General healthcare legislation impacting revenueCongress"Recent bill_impacts shows 8 healthcare bills with impact_ratios 0.0002-0.0003, estimated revenue impacts $3.19M-$6.06M"
Regulatory opportunities
-
Potential favorable healthcare legislationCongress"Recent bill_impacts shows multiple healthcare bills, though impact ratios are low (0.0002-0.0003)"
Capitol Hill AlliesChampions & critics
Congressional champions
- Unknown Unknown
Congressional critics
- No specific congressional critics identified.
Live signals + predictions for ROIV — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades ROIV
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord